Navigating the uncharted territory of aggressive maxillary sinus cancer: insights from a singular case
DOI:
https://doi.org/10.12923/cipms-2025-0022Keywords:
maxillary sinus cancer, MSC, case study, palliative chemotherapyAbstract
Maxillary sinus carcinoma (MSC) is a rare malignancy characterized by diagnostic and therapeutic complexity, often presenting late in its clinical course. This report details a unique and aggressive case of MSC in a 57-year-old male. Despite prompt multimodal treatment, including surgery, radiochemotherapy (RCTH) and sequential lines of palliative chemotherapy (CTH), the disease demonstrated rapid progression and resistance to standard therapies. Management was guided by a patient-centered approach, emphasizing shared decision-making in light of the patient’s clinical trajectory and quality-of-life considerations. This case highlights the challenges of treating aggressive MSC and underscores the necessity for individualized care strategies in managing rare and refractory head and neck cancers.
References
1. Sakashita T, Homma A, Hatakeyama H, Kano S, Mizumachi T, Furusawa J, et al. Salvage operations for patients with persistent or recurrent cancer of the maxillary sinus after superselective intra-arterial infusion of cisplatin with concurrent radiotherapy. Br J Oral Maxillofac Surg. 2014;52(4):323-8.
2. Kosugi Y, Suzuki M, Fujimaki M, Ohba S, Matsumoto F, Muramoto Y, et al Radiologic criteria of retropharyngeal lymph node metastasis in maxillary sinus cancer. Radiat Oncol. 2021;16:1-6.
3. d’Errico A, Pasian S, Baratti A, Zanelli R, Alfonzo S, Gilardi L, et al. A case-control study on occupational risk factors for sino-nasal cancer. OEM. 2009;66(7):448-55.
4. Won HS, Chun SH, Kim B-S, Chung SR, Yoo IR, Jung C-K,et al. Treatment outcome of maxillary sinus cancer. Rare Tumors. 2009; 1(2):110-4.
5. Santos MRM, Servato JPS, Cardoso SV, de Faria PR, Eisenberg ALA, Dias FL, Loyola AM. Squamous cell carcinoma at maxillary sinus: clinicopathologic data in a single Brazilian institution with review of literature. Int J Clin Exp Pathol. 2014;7(12):8823.
6. Ramachamparambathu AK, Vengal M, Mufeed A, Siyo N, Ahmed A. Carcinoma of maxillary sinus masquerading as odontogenic infection. JCDR. 2016;10(9):ZD11.
7. Kuo Y-H, Lin C-S. Regression of advanced maxillary sinus cancer with orbital invasion by combined chemotherapy and immunotherapy: A one-year follow-up case report. Mol Clin Oncol. 2022;16(4):94.
8. Rho H-J, Kim S-J, Nam H, Kim B, Kim I, Kim Y-K, et al. Detection and prediction of local recurrence of maxillary sinus cancer using F-18 FDG PET/CT. EJSO. 2010;36(2):214-20.
9. Blanco AI, Chao KC, Ozyigit G, Adli M, Thorstad WL, Simpson JR, et al. Carcinoma of paranasal sinuses: long-term outcomes with radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59(1):51-8.
10. Ashraf M, Biswas J, Dam A, Bhowmick A, Sing V, Nayak S. Results of treatment of squamous cell carcinoma of maxillary sinus: a 26-year experience. World J Oncol. 2010;1(1):28.
11. Noronha V, Patil VM, Joshi A, Krishna MV, Dhumal S, Juvekar S, et al. Induction chemotherapy in technically unresectable locally advanced carcinoma of maxillary sinus. Chemother Res Pract. 2014;2014(1):487872.
12. Amendola BE, Eisert D, Hazra TA, King ER. Carcinoma of the maxillary antrum: surgery or radiation therapy? Int J Radiat Oncol Biol Phys. 1981;7(6):743-6.
13. St.‐Pierre S, Baker SR. Squamous cell carcinoma of the maxillary sinus: analysis of 66 cases. Otolaryngol Head Neck Surg. 1983; 5(6):508-13.
14. Paulino AC, Marks JE, Bricker P, Melian E, Reddy SP, Emami B. Results of treatment of patients with maxillary sinus carcinoma. Cancer. 1998;83(3):457-65.
15. Hanna EY, Cardenas AD, DeMonte F, Roberts D, Kupferman M, Weber R, et al. Induction chemotherapy for advanced squamous cell carcinoma of the paranasal sinuses. Arch Otolaryngol Head Neck Surg. 2011;137(1):78-81.
16. Kim WT, Nam J, Ki YK, Lee JH, Kim DH, Park D, et al. Neoadjuvant intra-arterial chemotherapy combined with radiotherapy and surgery in patients with advanced maxillary sinus cancer. Radiat Oncol J. 2013;31(3):118.
17. Shiga K, Yokoyama J, Hashimoto S, Saijo S, Tateda M, Ogawa T, et al. Combined therapy after superselective arterial cisplatin infusion to treat maxillary squamous cell carcinoma. Otolaryngol Head Neck Surg. 2007;136(6):1003-9.
18. Yi KI, Kim SD, Mun SJ, Roh HJ, Cho KS. Therapeutic efficacy of regional and systemic chemotherapy in advanced maxillary sinus cancer. Head Neck Pathol. 2019;41(8):2732-40.
19. Xiang JJ, Uy NF, Minja FJ, Verter EE, Burtness BA. Hyperprogression after one dose of nivolumab in sinonasal cancer: a case report. Laryngoscope. 2020;130(4):907-10.
20. Yazici G, Gullu I, Cengiz M, Elmali A, Yilmaz MT, Aksoy S, et al.The synergistic effect of immune checkpoint blockade and radiotherapy in recurrent/metastatic sinonasal cancer. Cureus. 2018;10(10).
21. Guram K, Nunez M, Einck J, Mell LK, Cohen E, Sanders PD, et al. Radiation therapy combined with checkpoint blockade immunotherapy for metastatic undifferentiated pleomorphic sarcoma of the maxillary sinus with a complete response. Front Oncol. 2018;8:435.
22. da Silva Leonel ACL, Bonan RF, Pinto MBR, Kowalski LP, da Cruz Perez DE. The pesticides use and the risk for head and neck cancer: A review of case-control studies. Medicina Oral, Patología Oral y Cirugía Bucal. 2020;26(1):e56.
23. Amizadeh M, Safari-Kamalabadi M, Askari-Saryazdi G, Amizadeh M, Reihani-Kermani H. Pesticide exposure and head and neck cancers: a case-control study in an agricultural region. Iran J Otorhinolaryngol. 2017;29(94):275.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
